Trial of oral miltefosine for visceral leishmaniasis

Lancet

Volumn 352, Issue 9143, 1998, Pages 1821-1823

  Sundar, Shyam ^a   Rosenkaimer, Frank ^b   Makharia, Manoj K ^a   Goyal, Ashish K ^a   Mandal, Ashim K ^a   Voss, Andreas ^b   Hilgard, Peter ^b   Murray, Henry W ^c,d  

^a BANARAS HINDU UNIVERSITY   (India)

^b ASTA MEDICA AG   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ANTINEOPLASTIC AGENT; MILTEFOSINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDIA; KIDNEY FAILURE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN SIZE; TIME; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

EID: 0032488285     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04367-0     Document Type: Article

References (20)

1. 1 Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
2. 2 Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet 1990; 336: 1582-83.
3. 3 Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993; 9: 323-28.
4. 4 Sherwood JA, Gachihi GS, Muigai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinolone (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19: 1034-39.
5. 5 Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet 1996; 348: 614.
6. 6 Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995; 73: 191-97.
7. 7 Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin B versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344: 1599-600.
8. 8 Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938-43.
9. 9 Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Shortcourse, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133-37.
10. 10 Jha TK, Olliaro P, Thakur CPN, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 361: 1200-05.
11. 11 Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 176: 1117-19.
12. 12 Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin B versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340: 1256-57.
13. 13 Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic tumours. J Cancer Res Clin Oncol 1992; 118: 606-08.
14. 14 Danhauser-Riedl S, Drozd A, Zafferani M, et al. Phase I study of weekly oral miltefosine (hexadecyl-phosphocholine) in cancer patients. Onkologie 1991; 14: 392-400.
15. 15 Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-34.
16. 16 Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllsophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38: 1041-47.
17. 17 Hochhuth CH, Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine induces interferon-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 1992; 141: 161-68.
18. 18 Zeisig R, Rudolf M, Eue I, Arndt D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol 1995; 121: 69-75.
19. 19 Investigators Brochure. Miltex (INN Miltefosine). ASTA Medica. 1995.
20. 20 Breiser A, Kim D-J Fleer EAM, et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987; 22: 925-26.